

3.1 患者背景一覽表

3.1.1 患者背景一覽

患者背景		血縁者間 骨髓移植	血縁者間末梢血 幹細胞移植	非血縁者間 骨髓移植	臍帯血移植	合計
患者数		1939	2287	4654	3501	12381
性別	男	1091 (56.3%)	1327 (58.0%)	2759 (59.3%)	2055 (58.7%)	7232 (58.4%)
	女	848 (43.7%)	960 (42.0%)	1895 (40.7%)	1446 (41.3%)	5149 (41.6%)
	不明・未記載	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
年齢	0-17	628 (32.3%)	196 (8.6%)	664 (14.3%)	636 (18.2%)	2124 (17.2%)
	18-55	1032 (53.2%)	1501 (65.6%)	2838 (61.0%)	1769 (50.5%)	7140 (57.7%)
	56-	279 (14.4%)	590 (25.8%)	1152 (24.7%)	1096 (31.3%)	3117 (25.2%)
	不明・未記載	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
診断	AML	591 (30.5%)	903 (39.5%)	1761 (37.8%)	1597 (45.6%)	4852 (39.2%)
	ALL	498 (25.7%)	374 (16.4%)	898 (19.3%)	627 (17.9%)	2397 (19.4%)
	ATL	57 (2.9%)	114 (5.0%)	242 (5.2%)	119 (3.4%)	532 (4.3%)
	CML	47 (2.4%)	55 (2.4%)	117 (2.5%)	85 (2.4%)	304 (2.5%)
	MDS	164 (8.5%)	186 (8.1%)	483 (10.4%)	299 (8.5%)	1132 (9.1%)
	NHL	146 (7.5%)	342 (15.0%)	502 (10.8%)	346 (9.9%)	1336 (10.8%)
	固形腫瘍	45 (2.3%)	33 (1.4%)	9 (0.2%)	75 (2.1%)	162 (1.3%)
	その他	391 (20.2%)	280 (12.2%)	642 (13.8%)	353 (10.1%)	1666 (13.5%)
移植時病期	CR	903 (46.6%)	870 (38.0%)	2297 (49.4%)	1312 (37.5%)	5382 (43.5%)
	Non-CR	671 (34.6%)	1252 (54.7%)	1908 (41.0%)	1895 (54.1%)	5726 (46.2%)
	その他	295 (15.2%)	86 (3.8%)	342 (7.3%)	197 (5.6%)	920 (7.4%)
	不明・未記載	70 (3.6%)	79 (3.5%)	107 (2.3%)	97 (2.8%)	353 (2.9%)
BU剤型	BU (経静脈)を含むレジメン	409 (91.9%)	697 (83.4%)	1365 (87.5%)	748 (89.8%)	3219 (87.6%)
	BU (経口)を含むレジメン	36 (8.1%)	139 (16.6%)	195 (12.5%)	85 (10.2%)	455 (12.4%)
前治療レジメン	BU (経静脈)+CY±other	168 (13.0%)	185 (12.8%)	450 (12.1%)	118 (4.2%)	921 (10.0%)
	CY+TBI±other	660 (51.2%)	544 (37.5%)	1641 (44.2%)	1000 (35.7%)	3845 (41.6%)
	BU (経静脈)+FL±other	206 (16.0%)	469 (32.3%)	877 (23.6%)	581 (20.7%)	2133 (23.1%)
	FL+TBI±other	256 (19.8%)	252 (17.4%)	742 (20.0%)	1102 (39.3%)	2352 (25.4%)
GVHD予防薬	MTX+CyA	1108 (57.1%)	1130 (49.4%)	792 (17.0%)	937 (26.8%)	3967 (32.0%)
	MTX+FK506	531 (27.4%)	450 (19.7%)	3598 (77.3%)	1094 (31.3%)	5673 (45.8%)
	その他	300 (15.5%)	707 (30.9%)	264 (5.7%)	1470 (42.0%)	2741 (22.1%)

略語	
BU	Busulfan
CY	Cyclophosphamide
TBI	Total body irradiation
FL	Fludarabine phosphate
CI	Confidence interval
N	Number of cases observed